: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2017 Financial Results Utica, New York

CONMED Corporation Announces

First Quarter 2017 Financial Results

Utica, New York, April 26,

2017 --- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the first quarter ended March 31, 2017.

First Quarter 2017 Highlights

"We are encouraged by our first

quarter results, which exhibited continued strength across our key international markets, as well as solid performance within our

U.S. General Surgery business. While our domestic Orthopedics business remains a challenge, the first quarter represents improved

sequential performance, and we remain focused on returning this business to positive growth," commented Curt R. Hartman,

CONMED's President and Chief Executive Officer.

For the quarter ended March 31,

2017, domestic sales, which represented 53.3% of total revenue, increased 3.5%, as year-over-year growth of 9.5% in General Surgery

was partially offset by a decline of 3.7% in Orthopedics. International sales, which represented 46.7% of total revenue, increased

2.4% compared to the first quarter of 2016 on a reported basis. Foreign currency exchange rates, including the effects of the FX

hedging program, had a negative impact of $1.3 million on first quarter sales. In constant currency, international sales increased

3.9% versus the prior-year period.

For the quarter ended March 31,

2017, reported net loss totaled $4.5 million, compared to a reported net loss of $2.3 million a year ago. Reported diluted net

loss per share was $0.16 in the quarter, compared to a reported diluted net loss per share of $0.08 in the prior-year period. Reported

net loss for 2017 includes litigation, business acquisition, and restructuring costs, and reported net loss for 2016 includes business

acquisition, restructuring, and debt refinancing costs. The increase in reported net loss resulted primarily from the $12.2 million

Lexion case jury verdict against the Company in 2017, which was partially offset by lower acquisition related costs when compared

to the prior period. The effect of each of these items on reported net loss and reported diluted net loss per share appears in

the reconciliation of GAAP to non-GAAP measures below.

The Company excludes the after-tax

costs of special items including litigation, acquisitions, restructurings, gains on the sale of assets, debt refinancings, as well

as amortization of intangible assets, net of tax, from its adjusted diluted net earnings per share. Excluding the impact of these

items, adjusted net earnings(2) of $10.6 million decreased 8.7% year over year and adjusted diluted net earnings per

share(1) of $0.38 decreased 9.5% year over year. The decrease in adjusted net earnings resulted primarily from the unfavorable

impact of foreign exchange rates, partially offset by higher sales growth.

There is no change to CONMED's

previously issued financial guidance. The Company continues to expect 2017 constant currency sales growth in the range of 1% to

3%. Based on exchange rates as of April 21, 2017, the negative impact to 2017 sales from foreign exchange is still anticipated

to be approximately 0.5%.

In addition, the Company continues

to expect adjusted diluted net earnings per share in the range of $1.85 to $1.95, which includes an estimated negative impact from

foreign exchange based on exchange rates as of April 21, 2017. The adjusted diluted net earnings per share estimates for 2017 exclude

the cost of special items including acquisition costs, litigation costs, and restructuring costs, which are now estimated in the

range of $16.5 to $18.5 million, net of tax, and amortization of intangible assets, which are still estimated in the range of $12

to $14 million, net of tax.

Supplemental Financial Disclosures

(1) A reconciliation

of reported diluted net loss per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) A reconciliation

of reported net loss to adjusted net earnings, a non-GAAP financial measure, appears below.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its first quarter 2017 results.

To participate in the conference

call, dial 844-889-7792 (domestic) or 661-378-9936 (international)

and enter the passcode 4521460.

This conference call will also

be webcast and can be accessed from the "Investors" section of CONMED's web site at www.conmed.com.

The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Wednesday, April 26, 2017, until 7:30 p.m. ET on Wednesday, May 10, 2017. To hear this recording,

dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 4521460.

About CONMED Corporation

CONMED is a medical technology

company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used

by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50% of the Company's

total sales. Headquartered in Utica, New York, the Company employs approximately 3,300 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's

conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risk

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding

specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted income tax expense; adjusted

effective income tax rate; adjusted net earnings and adjusted diluted net earnings per share (EPS). The Company believes that these

non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and

assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other

adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative

of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company's underlying

business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects

of the Company's cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing

potential future business trends in connection with its budget process and bases certain management incentive compensation on these

non-GAAP financial measures.

To measure percentage sales growth

in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability

and trend of sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that

affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not

be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating

Because non-GAAP financial measures

are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures

having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for

reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, income tax expense,

effective income tax rate, net earnings (loss) and diluted net earnings (loss) per share, the most directly comparable GAAP financial

measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company's operations that, when